As noted in our September 2009 post discussing China's new National Essential Drug System (NEDS), China continues to make progress in its healthcare reform efforts. However, new national drug lists and price caps designed to provide low-cost drugs to the masses, have at the same time raised questions about the program's economic impact on local and multinational pharmaceutical manufacturers. To learn more about how China's healthcare reform package and how it may affect your company, we invite you to read Reed Smith Life Sciences Partner Gordon Schatz and ZS Associates Inc. consultant Patrick Nowlin's "Drugs for the Masses," recently published by China Business Review.… Continue Reading